Suppr超能文献

急性脑出血的药物治疗

Medical management of acute intracerebral hemorrhage.

作者信息

Anderson Craig S

机构信息

The George Institute for International Health, The Royal Prince Alfred Hospital and University of Sydney, New South Wales, Australia.

出版信息

Curr Opin Crit Care. 2009 Apr;15(2):93-8. doi: 10.1097/MCC.0b013e328325d12c.

Abstract

PURPOSE OF REVIEW

Intracerebral hemorrhage (ICH) is the most serious but least treatable form of stroke, with prognosis critically dependent on both the size and degree of hematoma expansion. Treatments that target hematoma expansion offer potential to improve outcomes. This review analyzes the recent literature pertaining to the medical management of ICH.

RECENT FINDINGS

Modern imaging studies have confirmed the dynamic nature of ICH. At least one-third of patients experience significant continued bleeding and hematoma expansion in the first few hours after onset, more so in warfarin-related ICH. Despite a strong biological rationale for benefit, a large clinical trial of recombinant activated factor VII failed to show any treatment effects on substantive outcomes despite clear attenuation of hematoma growth. The impact of recombinant activated factor VII is therefore severely restricted because of uncertain efficacy, definite hazard, and high cost. Accumulating evidence indicates beneficial effects from the early normalization of international normalized ratio levels and replacement of coagulation factors in warfarin-related ICH. Although high blood pressure (BP) is common and associated with poor outcomes in ICH, there is insufficient evidence to recommend a specific early BP management strategy, although recent randomized evidence indicates that such treatment is well tolerated and readily incorporated into routine clinical practice. Definitive evidence to support a low-cost, widely applicable treatment is urgently required for a condition in which therapy is primarily supportive.

SUMMARY

In patients with acute ICH, rapid intensive BP-lowering treatment may provide protection against hematoma growth without concerns about safety and tolerability. How well such treatment can translate into overall benefits to patients is yet to be determined. At present, recombinant activated factor VII cannot be recommended for routine use, although BP lowering should generally follow conservative guidelines.

摘要

综述目的

脑出血(ICH)是最严重但治疗手段最少的卒中类型,其预后严重依赖于血肿大小及扩大程度。针对血肿扩大的治疗方法有望改善预后。本综述分析了近期有关脑出血药物治疗的文献。

最新发现

现代影像学研究已证实脑出血具有动态变化特性。至少三分之一的患者在发病后的最初数小时内会出现显著的持续出血及血肿扩大,在与华法林相关的脑出血中更为常见。尽管有强有力的生物学依据支持其有益性,但一项关于重组活化因子VII的大型临床试验未能显示出对实质性结局有任何治疗效果,尽管血肿生长明显得到抑制。因此,由于疗效不确定、存在明确风险且成本高昂,重组活化因子VII的影响受到严重限制。越来越多的证据表明,在与华法林相关的脑出血中,早期使国际标准化比值水平正常化及补充凝血因子具有有益作用。尽管高血压在脑出血中很常见且与不良预后相关,但尚无足够证据推荐特定的早期血压管理策略,不过近期的随机试验证据表明这种治疗耐受性良好且易于纳入常规临床实践。对于主要依靠支持性治疗的疾病,迫切需要有确凿证据支持低成本、广泛适用的治疗方法。

总结

在急性脑出血患者中,快速强化降压治疗可能预防血肿生长,且无需担心安全性和耐受性问题。这种治疗能在多大程度上转化为对患者的总体益处尚待确定。目前,不推荐常规使用重组活化因子VII,尽管降压一般应遵循保守的指导原则。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验